Santo Spirito Hospital, Viale Giolitti 3, 15033 Casale Monferrato (AL), Italy.
Expert Rev Anticancer Ther. 2010 Jul;10(7):1031-5. doi: 10.1586/era.10.92.
Agonistic analogs of luteinizing hormone-releasing hormones are indicated for the palliative treatment of metastatic prostate cancer. While the prognostic role of prostate-specific antigen in patients submitted to androgen-deprivation therapy has been extensively investigated in these patients, there is no consensus about the utility of serum testosterone measurements during follow-up and about their possible prognostic value. Recent reports have shown that testosterone levels might be directly related to survival and risk of death. These results need to be confirmed by further prospective studies. Given this concept, lowering testosterone as much as possible should be the goal of androgen-deprivation therapy in patients with metastatic prostate cancer, as this may have an impact on patient survival.
促黄体生成素释放激素激动剂适用于转移性前列腺癌的姑息治疗。虽然在接受去势治疗的患者中，前列腺特异性抗原在预后中的作用已经得到了广泛研究，但对于在随访期间测量血清睾酮的意义及其可能的预后价值，尚无共识。最近的报告显示，睾酮水平可能与生存和死亡风险直接相关。这些结果需要进一步的前瞻性研究来证实。考虑到这一概念，尽可能降低睾酮水平应该是转移性前列腺癌患者去势治疗的目标，因为这可能会对患者的生存产生影响。
